TY - JOUR
T1 - Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure
T2 - The valsartan heart failure trial (Val-HEFT)
AU - Latini, Roberto
AU - Masson, Serge
AU - Anand, Inder
AU - Judd, Dianne
AU - Maggioni, Aldo P.
AU - Chiang, Yann Tong
AU - Bevilacqua, Maurizio
AU - Salio, Monica
AU - Cardano, Paola
AU - Dunselman, Peter H J M
AU - Holwerda, Nicolaas J.
AU - Tognoni, Gianni
AU - Cohn, Jay N.
PY - 2002/11/5
Y1 - 2002/11/5
N2 - Background - Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known. Methods and Results - Both BNP and NE were measured in 4284 patients randomized to valsartan or placebo in the Valsartan Heart Failure Trial (Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan were tested by ANCOVA, controlling for baseline values and concomitant ACE inhibitors and/or β-blockers. BNP and NE concentrations were similar at baseline in the 2 groups and were decreased by valsartan starting at 4 months and up to 24 months. BNP increased over time in the placebo group. At the end point, least-squares mean (±SEM) BNP increased from baseline by 23±5 pg/mL in the placebo group (n=1979) but decreased by 21±5 pg/mL (n=1940) in the valsartan group (P
AB - Background - Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The long-term effects of angiotensin receptor blockers on BNP and NE in heart failure patients are not known. Methods and Results - Both BNP and NE were measured in 4284 patients randomized to valsartan or placebo in the Valsartan Heart Failure Trial (Val-HeFT) at baseline and 4, 12, and 24 months after randomization. The effects of valsartan were tested by ANCOVA, controlling for baseline values and concomitant ACE inhibitors and/or β-blockers. BNP and NE concentrations were similar at baseline in the 2 groups and were decreased by valsartan starting at 4 months and up to 24 months. BNP increased over time in the placebo group. At the end point, least-squares mean (±SEM) BNP increased from baseline by 23±5 pg/mL in the placebo group (n=1979) but decreased by 21±5 pg/mL (n=1940) in the valsartan group (P
KW - Angiotensin
KW - Heart failure
KW - Natriuretic peptides
KW - Norepinephrine
KW - Trials
UR - http://www.scopus.com/inward/record.url?scp=0037027511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037027511&partnerID=8YFLogxK
U2 - 10.1161/01.CIR.0000036747.68104.AC
DO - 10.1161/01.CIR.0000036747.68104.AC
M3 - Article
C2 - 12417542
AN - SCOPUS:0037027511
VL - 106
SP - 2454
EP - 2458
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 19
ER -